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The antiapoptotic Bcl-2 and Bcl-xL proteins of mammals are converted into potent proapoptotic factors when
they are cleaved by caspases, a family of apoptosis-inducing proteases (E. H.-Y. Cheng, D. G. Kirsch, R. J.
Clem, R. Ravi, M. B. Kastan, A. Bedi, K. Ueno, and J. M. Hardwick, Science 278:1966–1968, 1997; R. J. Clem,
E. H.-Y. Cheng, C. L. Karp, D. G. Kirsch, K. Ueno, A. Takahashi, M. B. Kastan, D. E. Griffin, W. C. Earnshaw,
M. A. Veliuona, and J. M. Hardwick, Proc. Natl. Acad. Sci. USA 95:554–559, 1998). Gamma herpesviruses also
encode homologs of the Bcl-2 family. All tested herpesvirus Bcl-2 homologs possess antiapoptotic activity,
including the more distantly related homologs encoded by murine gammaherpesvirus 68 (gHV68) and bovine
herpesvirus 4 (BHV4), as described here. To determine if viral Bcl-2 proteins can be converted into death
factors, similar to their cellular counterparts, five herpesvirus Bcl-2 homologs from five different viruses were
tested for their susceptibility to caspases. Only the viral Bcl-2 protein encoded by gHV68 was susceptible to
caspase digestion. However, unlike the caspase cleavage products of cellular Bcl-2, Bcl-xL, and Bid, which are
potent inducers of apoptosis, the cleavage product of gHV68 Bcl-2 lacked proapoptotic activity. KSBcl-2,
encoded by the Kaposi’s sarcoma-associated herpesvirus, was the only viral Bcl-2 homolog that was capable of
killing cells when expressed as an N-terminal truncation. However, because KSBcl-2 was not cleavable by
caspases, the latent proapoptotic activity of KSBcl-2 apparently cannot be released. The Bcl-2 homologs
encoded by herpesvirus saimiri, Epstein-Barr virus, and BHV4 were not cleaved by apoptotic cell extracts and
did not possess latent proapoptotic activities. Thus, herpesvirus Bcl-2 homologs escape negative regulation by
retaining their antiapoptotic activities and/or failing to be converted into proapoptotic proteins by caspases
during programmed cell death.
The bcl-2 gene was identified at chromosomal translocation
breakpoints in follicular lymphomas and contributes to tumor-
igenesis by inhibiting programmed cell death rather than by
stimulating cell growth (1, 59). Bcl-2 protein is normally ex-
pressed in a wide range of tissues and is required for normal
development and maintenance of the immune system (61).
More than 15 cellular Bcl-2-related proteins have been iden-
tified in a wide range of species. In addition, Bcl-2 homologs
are also found in viral genomes, including oncogenic herpes-
viruses and the unrelated African swine fever virus (2, 23).
Interestingly, all sequenced herpesviruses of the gamma sub-
family, including Epstein-Barr virus (EBV), herpesvirus saimiri
(HVS), mouse gammaherpesvirus 68 (gHV68), bovine herpes-
virus 4 (BHV4) Kaposi’s sarcoma-associated herpesvirus
(KSHV)/human herpesvirus 8, equine herpesvirus 2, and ate-
line herpesvirus 3 encode a Bcl-2-like protein, implying a con-
served requirement for viral Bcl-2 proteins.
The function of cellular Bcl-2 family members is regulated in
part by caspases. We and others have reported that caspase-3
cleaves Bcl-2 at Asp-34 and Bcl-xL at Asp-61 and Asp-76 to
produce N-terminally truncated proteins that have lost their
antiapoptotic activities (8, 13, 20, 22, 35). These cleavages are
likely to be physiologically significant, as mutation of the cleav-
age sites in Bcl-2 and Bcl-xL enhances their antiapoptotic ac-
tivities (8, 13). The caspase cleavage products of Bcl-2 and
Bcl-xL are potently proapoptotic, based on transfection studies
expressing protein fragments that are equivalent to caspase
cleavage products (8, 13). Furthermore, apoptosis induced by
these fragments is blocked by the baculovirus caspase inhibitor
P35, suggesting that these fragments kill cells in a caspase-
dependent manner. Thus, the generation of these fragments
inside cells may accelerate cell death by amplifying the caspase
cascade. In support of this hypothesis, N-terminally truncated
Bcl-2 triggers the release of cytochrome c from mitochondria,
similar to Bax (32, 35). Several groups have found that Bax and
Bid are also cleaved during apoptosis, and their cleavage prod-
ucts are potently proapoptotic (35, 41, 43, 44, 66). Therefore,
the cleavage products of Bcl-2-related proteins may be impor-
tant facilitators of apoptosis in vivo.
The viral Bcl-2 homologs differ in interesting ways from their
cellular counterparts with regard to their effects on cell cycle
progression and their abilities to heterodimerize with other
Bcl-2 family members (24). Here we report another important
mechanistic difference between viral and cellular Bcl-2 pro-
teins. Herpesvirus Bcl-2 homologs appear to have captured the
antiapoptotic functions but eliminated the proapoptotic func-
tions of their cellular counterparts. Thus, these viral proteins
may represent constitutively active antiapoptotic versions that
escape negative regulation by caspases because they fail to be
converted into proapoptotic proteins.
MATERIALS AND METHODS
Plasmids and viruses. PCR-amplified full-length or truncated Bcl-2 open
reading frames were cloned into pSG5 or a modified pSG5 vector containing a
hemagglutinin (HA) epitope tag (pHYC79), and the correct sequence was con-
* Corresponding author. Mailing address: Dept. of Molecular Mi-
crobiology and Immunology, Johns Hopkins, E5132 SPH, 615 North
Wolfe St., Baltimore, MD 21205. Phone: (410) 955-2716. Fax: (410)
955-0105. E-mail: hardwick@jhu.edu.
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firmed by DNA sequencing. Restriction fragments containing the HA-tagged or
untagged Bcl-2 family members were excised from the pSG5 derivatives and
inserted at the BstEII site of the Sindbis virus vector dsTE12Q, and recombinant
viruses were generated as previously reported (9, 39). Protein expression of the
untagged constructs was confirmed by in vitro translation with [35S]methionine
using T7 quick-coupled TNT (Promega) and resolved by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and autoradiography.
Cleavage assays. In vitro cleavage reactions contained 1 ml of 35S-labeled in
vitro translation mixture and 1 ml of purified caspase-1 (95 U), caspase-3 (1,600
U), or caspase-8 (260 U), where 1 U generates 1 pmol of 7-amino-4-methylcou-
marin (AMC) per min by using saturating substrate Ac-YVAD-AMC or Ac-
DEVD-AMC (Peptides International) at 25°C. Dithiothreitol was added to a
final concentration of 10 mM, and caspase reaction buffer (100 mM HEPES [pH
7.5], 10% sucrose, 0.1% CHAPS [3-[(3-cholamidopropyl)-dimethylammonio]-1-
propanesulfonate]) was added to bring the total reaction volume to 10 ml. After
digestion for 3 h at 37°C, the labeled proteins were analyzed by SDS-PAGE and
autoradiography after enhancing with 1 M salicylic acid.
Apoptotic 293 cell extracts were prepared as previously described (18). Cleav-
age reactions contained 2 ml of 35S-labeled in vitro translation mix and 10 ml of
293 lysate or caspase reaction buffer. ATP (Boehringer Mannheim) was added to
a final concentration of 1 mM, and the reaction mixtures were incubated at 37°C
overnight and analyzed as described above.
Virus infection and cell transfection. Low-passage-number (,15) BHK-21
cells (American Type Culture Collection) were infected with 5 PFU of recom-
binant Sindbis virus vectors per cell in a reduced volume of infection medium
(Dulbecco’s modified Eagle’s medium supplemented with 1% fetal bovine se-
rum) for 1 h and then returned to 10% serum for 48 h. Infections were per-
formed in duplicate, blinded, and at least 500 cells were counted per sample.
BHK-21 or Cos-1 cells were transfected with 0.5 mg of lacZ reporter plasmid
pCH110 and various amounts of Bcl-2 plasmid using Lipofectamine (Life Tech-
nologies). The total amount of plasmid transfected was held constant at 2.5 mg
by using empty pSG5 vector. Alternatively, Cos-1 cells were transfected with 2 mg
of plasmid containing procaspase-3 and 0.5 mg of bcl-2 plasmid. At 24 h post-
transfection, the cells were fixed with 0.5% glutaraldehyde in phosphate-buffered
saline and stained with 5-bromo-4-chloro-3-indolyl-b-D-galactoside (49). Cell
viability of blinded samples was determined by counting the number of blue cells
in 10 high-power fields and scoring for normal versus apoptotic morphology.
Immunoblot analysis. Cos-1 cells were lysed at 24 h posttransfection in radio-
immunoprecipitation assay buffer (150 mM NaCl, 1.0% NP-40, 0.5% deoxy-
cholate, 1.0% SDS, 50 mM Tris [pH 8.0]) containing the protease inhibitors
aprotinin, benzamidine, chymostatin, leupeptin, pepstatin A, and phenylmethyl-
sulfonyl fluoride. Protein (50 mg, quantitated by the bicinchoninic acid assay;
Pierce) was separated by SDS–15% PAGE, transferred to nitrocellulose (Schlei-
cher and Schuell), probed with anti-hBcl-2 monoclonal antibody (MAb) (pro-
vided by David Mason), anti-HA MAb 12CA5 (Berkeley), or anti-caspase-3
antibody and detected using SuperSignal (Pierce).
RESULTS
Homology domains of viral and cellular Bcl-2 family mem-
bers. The mammalian Bcl-2 family is defined by the homology
domains BH1 to BH4. The most conserved of these are the
BH1 and BH2 domains, which are important for antiapoptotic
activity and dimerization (9, 67). In addition, the BH1-BH2
region spans alpha helices 5 and 6, which are implicated in ion
channel activity (48). A multiple alignment revealed that the
BH1 homology domain is the most highly conserved domain
among gamma herpesvirus Bcl-2 homologs (Fig. 1). The BH2
domain is also conserved with the exception of gHV68, which
surprisingly lacks a recognizable BH2 domain (Fig. 1). The cell
homologs and BHRF1 from Epstein-Barr virus were shown to
be anchored to cytoplasmic membranes via their hydrophobic
C termini (25, 52). The predicted amino acid sequence for the
other viral genes also contains a stretch of hydrophobic resi-
dues followed by one or more positively charged residues at
the C terminus. The original BHV4 genome sequence in Gen-
Bank apparently contains an error, causing a reading frame-
shift prior to the hydrophobic C terminus. The sequence of a
genomic fragment of BHV4 provided by Vicky Van Santen
(Auburn University) contains a 2-nucleotide insertion at posi-
tion 615 within the open reading frame (Fig. 1). Both gHV68
and BHV4 have additional amino acids after the last charged
residue, though the function of this C-terminal extension is not
known. The BH-3 domain is implicated in the cell-killing ac-
tivity of the proapoptotic Bcl-2 family members Bax and Bak
(11, 64), as well as the Bcl-2 cleavage product (8) and the more
distantly related proteins Bid and Bad (33, 65), but is poorly
conserved in the viral homologs. The prodeath activity of the
BH3 domain may be linked to its role in dimerization with
other Bcl-2 family members. The N-terminal BH4 domain,
which is required for the antiapoptotic activities of Bcl-2 and
Bcl-xL (27, 30), is poorly conserved even among the cellular
homologs. This domain is also poorly conserved in the viral
proteins. Similar to Bcl-2 and Bcl-xL, the Bcl-2 homolog encod-
ed by BHV4 contains a long “loop” domain stretching between
BH4 and BH3. However, there is no significant amino acid
similarity between any of the viral or cellular loop domains,
suggesting that they possess unique functions (Fig. 1). The re-
maining viral Bcl-2 proteins have much shorter loop domains,
many even shorter than that of Bax.
gHV68 and BHV4 Bcl-2 homologs possess antiapoptotic
activity. The viral Bcl-2 homologs from EBV, KSHV, and HVS
were shown previously to possess antiapoptotic activity (10, 15,
26, 46, 50, 53). Therefore, to determine if the more distantly
related Bcl-2 homologs encoded by gHV68 and BHV4 also
function as apoptosis inhibitors, they were cloned into the
Sindbis virus vector and tested for their ability to inhibit Sind-
bis virus-induced apoptosis in BHK cells. Sindbis virus induces
all the classic morphological and biochemical characteristics of
apoptosis in many cell types, including BHK cells, and has
proven to be a useful model for studying a variety of cell death
regulators, including viral Bcl-2 proteins (9, 10, 16, 40, 42, 51,
60). Both gHV68 and BHV4 Bcl-2 homologs with N-terminal
HA tags were capable of inhibiting apoptosis induced by Sind-
bis virus almost as efficiently as HA-tagged Bcl-xL despite
lower expression levels of the BHV4 Bcl-2, as measured by
immunoblot analysis with anti-HA antibody (Fig. 2). In con-
trast, a control protein (chloramphenicol acetyltransferase
[CAT]) lacked protective activity when expressed from the
Sindbis virus vector. Similar to the cellular proteins, deletion of
the BH4 domain of gHV68 abolished its ability to block Sind-
bis virus-induced apoptosis (data not shown).
Viral homologs escape cellular regulatory mechanisms. To
determine whether viral Bcl-2 homologs are susceptible to
caspase digestion, the viral proteins were translated in vitro
and treated with active recombinant purified caspase-1 (which
cleaves Bcl-xL), caspase-3 (which cleaves Bcl-xL and Bcl-2),
and caspase-8 (which cleaves Bid). Of the viral proteins, only
gHV68 Bcl-2 was susceptible to partial cleavage by caspase-3
(Fig. 3A), and none of the viral homologs was cleaved by
caspase-1 or caspase-8 (Fig. 3B) (data not shown). In contrast,
Bcl-xL was cleaved by caspase-1 to produce a 16-kDa fragment
and by caspase-3 to produce both the 16- and 14-kDa frag-
ments observed previously in vitro and in apoptotic cells (13,
20).
To further explore the possibility that viral Bcl-2 homologs
could be cleaved by caspases or other proteases during apo-
ptosis, in vitro-translated proteins were treated with apoptotic
extracts prepared from 293 cells, which contain a number of
activated caspases (18). Again only Bcl-xL and gHV68 Bcl-2
were cleaved (Fig. 4A and B). By analogy with Bcl-2 and
Bcl-xL, the gHV68 homolog is expected to be cleaved in the
loop region between BH4 and BH3. Immunoblot analysis ver-
ified that the gHV68 protease site is located in the N terminus,
because the cleavage product is not detected with an antibody
to the N-terminal HA tag (data not shown). Caspases cleave
exclusively after Asp residues, and there are three Asp residues
present in the loop region of gHV68 Bcl-2 (residues 28, 31,
and 37). The consensus cleavage site for caspase-3 is DXXD
(58), consistent with the gHV68 Bcl-2 sequence DCVD31
(bold in Fig. 1). Furthermore, the cleavage product of gHV68
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Bcl-2 migrates only slightly faster than that of a deletion mu-
tant lacking amino acids 2 to 28 (DN28), consistent with cleav-
age at Asp-31, Asp-37, or both (Fig. 4, compare last two lanes).
Except for KSBcl-2, encoded by KSHV, the viral Bcl-2 proteins
contain at least one Asp residue in this region, though none is
a consensus caspase-3 site. Other sequences as well as struc-
tural features are required to constitute a caspase cleavage site
because caspases are known to cleave only at specific Asp
residues. Therefore, it appears that caspases cleave and
inactivate only one of the herpesvirus Bcl-2 homologs tested.
However, it is not known if caspase cleavage of gHV68 Bcl-2
occurs during virus infection of mice.
To determine whether viral Bcl-2 proteins harbor latent
proapoptotic activity, C-terminal fragments of the viral pro-
teins were expressed in transfected cells. Constructs were gen-
erated to mimic potential caspase cleavage fragments, such
that all truncated proteins lacked the BH4 homology domain
and retained the BH3 domain. The arrowheads in Fig. 1 mark
the new N termini (plus an initiation Met). The exact positions
of the newly generated N termini may not be critical, as the
position of the caspase cleavage site is not conserved between
Bcl-2 and Bcl-xL. That is, Bcl-2 is cleaved on the N-terminal
side of the ;50-amino-acid loop domain, while Bcl-xL is
cleaved on the C-terminal side of the loop (bold in Fig. 1).
Furthermore, the 16-kDa Bcl-xL, 14-kDa Bcl-xL, and 23-kDa
Bcl-2 fragments all possess equivalent proapoptotic activities
in cultured cells (8, 20) (data not shown). Transfection of the
N-terminally truncated viral Bcl-2 constructs had no effect on
cell viability except for DN20 KSBcl-2, which killed cells in a
dose-dependent manner, similar to DN61 Bcl-xL (16-kDa frag-
ment) (Fig. 5). Similar results were obtained in Cos-1 cells
(data not shown). However, because the KSBcl-2 protein has
no potential caspase cleavage sites between BH4 and BH3 and
was not cleaved by recombinant caspases or apoptotic cell ex-
tracts, its proapoptotic function appears to remain latent. The
caspase cleavage product of gHV68 Bcl-2, the only cleavable
viral homolog, was not capable of killing BHK cells (Fig. 5).
Similar results were obtained in Cos-1 cells (data not shown).
Because of the lack of appropriate antibodies and because N-
and C-terminal tags impair the prodeath activities of truncated
Bcl-xL and KSBcl-2, all fragments were expressed without tags.
Therefore, all plasmid inserts were completely sequenced, and
protein expression was confirmed by in vitro translation of the
same plasmids used for transfection (Fig. 4 and data not shown).
FIG. 1. Amino acid alignment of viral and cellular Bcl-2 homologs. Human Bcl-2, human Bcl-xL, and human Bax are compared with the gammaherpesvirus Bcl-2
homologs ORF16 from KSHV (KSBcl-2), M11 of gHV68 (g68), ORF16 of HVS, BHRF1 of EBV, and BORFB2 of BHV4. Identical (dark shade) and similar (light
shade) amino acids occurring in four of the eight entries are marked. Homology domains BH1 to BH4 and the transmembrane domain (TM) are marked with horizontal
lines. The caspase recognition sites in Bcl-2 and Bcl-xL are in bold; arrowheads mark the N termini of truncated mutants. Stars indicate the hydrophobic residues in
the BH3 domain of Bak that are important for binding to Bcl-xL. The GenBank accession number for the corrected sequence data for BORFB2 of BHV4 is AF129421.
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These findings suggest that viral Bcl-2 homologs escape cel-
lular regulatory mechanisms by retaining their antiapoptotic
activities and/or by failing to be converted into proapoptotic
proteins when caspases are activated during apoptosis. To
compare KSBcl-2 with a cellular homolog in the presence of
activated caspases, cell viability was monitored in Cos-1 cells
that had been transfected with procaspase-3 and a Bcl-2 ho-
molog (Fig. 6). Caspase-3 was selected for this experiment
because it is an abundant downstream caspase and the only
caspase that cleaves viral and cellular Bcl-2 proteins (35).
Overexpression of procaspase-3 alone had no effect on cell
viability. However, overexpression of Bcl-2 alone exhibited
some intrinsic proapoptotic activity, a phenomenon previously
observed in many laboratories, including ours (8). When pro-
caspase-3 was cotransfected with human Bcl-2, cell viability
was further reduced concomitant with cleavage of Bcl-2 to its
23-kDa signature fragment. The Bcl-2 cleavage product was
shown previously to activate caspases by inducing release of
cytochrome c from mitochondria in a feed-forward pathway to
accelerate cell death (35). Consistent with this finding, cotrans-
fection of Bcl-2 and procaspase-3 resulted in processing of
procaspase-3 to its active form (Fig. 6). The caspase-3-medi-
ated enhancement of cell death was abolished by mutation of
the caspase-3 cleavage site in Bcl-2 (D34A). The faint Bcl-2
cleavage product observed with the D34A mutant in the pres-
ence of caspase-3 is probably due to inefficient cleavage at
Asp-31 (the P4 position in the DAGD34 site). Taken together,
these data indicate that the cell killing function of Bcl-2 is
enhanced when the proapoptotic fragment of Bcl-2 is released
by caspase cleavage. The observation that Bcl-2 induced cell
death(withoutcotransfectedcaspase-3)suggeststhattheproapo-
ptotic function of full-length Bcl-2 may be unleashed by mech-
anisms other than caspase cleavage. In contrast to human
Bcl-2, KSBcl-2 lacked intrinsic proapoptotic activity and failed
to enhance cell death relative to the control vector when co-
transfected with procaspase-3 (Fig. 6). In addition, KSBcl-2
had almost no ability to induce the processing of procaspase-3
to its active form. Thus, KSBcl-2 was not converted to a proapo-
ptotic form by caspase-3 or other cell factors.
DISCUSSION
Herpesvirus genomes contain large blocks of conserved
genes required for housekeeping functions. These blocks are
FIG. 2. BHV4 and gHV68 (g68) Bcl-2 proteins inhibit apoptosis. Apoptotic
cell morphology and viability were determined by light microscopy and trypan
blue dye exclusion, respectively, at 48 h postinfection of BHK cells with Sindbis
virus vectors encoding the indicated Bcl-2 homolog or control CAT. The means
and standard errors of the mean (SEM) are shown for three independent ex-
periments. All Bcl-2 homologs have N-terminal HA tags. A corresponding im-
munoblot analysis with anti-HA antibody is shown.
FIG. 3. Except for gHV68 (g68) Bcl-2, viral Bcl-2 homologs are not cleaved by caspases. The indicated 35S-labeled, in vitro-translated proteins were digested with
the indicated recombinant caspases or incubated with caspase buffer only (lane —). Proteins were analyzed by SDS-PAGE and autoradiography. Caspase activity was
determined by using peptide substrates as described in Materials and Methods. Minor bands that are present in both digested and undigested lanes are presumably premature
terminations, internal initiations, or nonspecific degradation products. For example, the ;26-kDa fragment of Bcl-xL is due to initiation at an internal Met at position 45 (13).
Molecular size markers are indicated (in kilodaltons). Brackets indicate the approximate positions of viral proteins lacking the N-terminal BH4 domain.
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separated by genes that are unique to herpesvirus subfamilies
or unique to a particular virus. Unlike other herpesviruses, the
gammaherpesvirus subfamily encodes a number of proteins
with obvious homology to cellular factors, such as cyclin D,
OX2, interleukin-8 receptor, interleukin-6, chemokines, che-
mokine receptors, interferon regulatory factors, FLIP proteins,
Bcl-2, and others (21). These factors were presumably acquired
as adaptations to a particular host environment and are can-
didate perpetrators of the distinct diseases and cancers asso-
ciated with these viruses. Some of these viral homologs have
expanded functions or escape regulatory mechanisms to which
their cellular counterparts are subject. KSHV encodes a G-
protein-coupled receptor (ORF74) that stimulates cell prolif-
eration and angiogenesis by a constitutive, agonist-indepen-
dent mechanism (3, 5). The viral chemokine encoded by KSHV,
vMIP-II, binds to a broader range of receptors with higher affin-
FIG. 4. Except for gHV68 (g68) Bcl-2, viral Bcl-2 proteins are resistant to cleavage by apoptotic cell extracts. In vitro-translated, 35S-labeled proteins were digested
with apoptotic 293 cell extracts (18). Proteins were analyzed by SDS-PAGE and autoradiography. Treated and untreated samples were run on the same gel with the
same exposure, though the lanes were rearranged for display. Longer gels confirmed the absence of detectable small cleavage products (data not shown). For an
explanation of minor bands in both digested and undigested samples, see the legend to Fig. 3. Molecular size markers are indicated (in kilodaltons). wt, wild type.
FIG. 5. Except for DN20 KSBcl-2, N-terminally truncated viral Bcl-2 proteins lack proapoptotic activity. Plasmids encoding wild-type Bcl-2 family members or
N-terminal truncations lacking the indicated number of amino acids were transfected into BHK cells at the indicated DNA concentrations. Cell viability was determined
at 24 h posttransfection by scoring the percentage of live/nonapoptotic versus total transfected cells (counting .250 lacZ-positive cells per sample). The data presented
are the means and SEM for three to six independent experiments.
5028 BELLOWS ET AL. J. VIROL.
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ity, functions as an antagonist of chemotaxis, and is a potent
angiogenic factor, unlike cellular MIP-1a and RANTES (7,
36). Our data suggest that like these factors, the gammaher-
pesvirus Bcl-2 homologs may be constitutively active. In this
way, viral Bcl-2 proteins are unlike several cellular Bcl-2 family
members that become potent killer proteins following proteo-
lytic cleavage. Consistent with this model, HVS Bcl-2 was
shown to protect Jurkat cells from Fas-induced apoptosis, in
contrast to human Bcl-2, which is cleaved by caspases in Jurkat
cells following Fas ligation (8, 15). While our paper was in
review, Wang et al. reported that gHV68 Bcl-2 inhibits Fas-
and tumor necrosis factor-induced apoptosis in HeLa cells
(63). Therefore, the Sindbis virus-induced apoptosis utilized in
our studies also reflects the results obtained with other cell
death stimuli.
Viral Bcl-2 proteins differ in other ways from their cellular
homologs. In contrast to Bcl-2, which suppresses cell cycle
progression (28), BHRF1 was reported to stimulate cell cycle
progression in some situations (14, 29). However, another
group reported that BHRF1 interferes with Ras-induced pro-
liferation, which can be relieved by amino acid substitutions in
the BH3 domain of BHRF1 (56). These disparate results could
potentially be explained by cell type-specific factors that mod-
ulate BHRF1 function (19).
Like human Bcl-2, herpesvirus Bcl-2 homologs can cooper-
ate with adenovirus E1A and c-Myc to facilitate cell transfor-
mation (17, 56), raising the possibility that viral Bcl-2 proteins
may contribute directly to the tumorigenic potential of several
of these viruses. This is consistent with the finding that the
gHV68 Bcl-2 homolog appears to be expressed during latency
in infected mice (62). In addition, viral Bcl-2 homologs may
serve to prevent premature cell death during virus replication,
fitting with the observation that several of the viral Bcl-2 ho-
mologs are synthesized during the lytic phase of the virus life
cycle (4, 10). Although an EBV mutant lacking its Bcl-2 ho-
molog (BHRF1) has no detectable phenotype in cell culture
(38, 45), natural isolates of EBV retain a functional BHRF1,
further suggesting its importance to the biology of the virus
(34).However,byanalogywithother largeDNAviruses,antiapo-
ptotic functions may be redundantly encoded (23). In fact, a
second Bcl-2 homolog encoded by EBV was recently reported
(46). Furthermore, the KSHV, equine herpesvirus 2, BHV4,
HVS, and ateline herpesvirus 3 viruses all encode viral FLIP
proteins that are implicated in blocking caspase recruitment to
cell death receptors (6, 57).
The BH3 domain is required and sufficient for the proapo-
ptotic activity of Bax and Bak in some assays (8, 11). Given that
the viral Bcl-2 proteins have lost their latent proapoptotic
activities (except for KSBcl-2), it is not surprising that the BH3
domain is less well conserved in the viral proteins. Based on
the nuclear magnetic resonance structure of a peptide of Bak
bound to Bcl-xL, the BH3 domain of Bak forms an alpha-helix
that inserts into a hydrophobic cleft on Bcl-xL, probably inac-
tivating its antiapoptotic activity (54). A comparison of the
structures of cleaved and uncleaved Bid suggests that cleavage
of Bid by caspase-8 exposes the Bid BH3 domain and may
contribute to reorientation of the Bid BH3 domain, making it
more available for binding partners (12, 47). Of the four hy-
drophobic amino acids in the Bak/Bid BH3 domain that insert
into the hydrophobic groove on Bcl-xL, only three of these are
conserved in the viral homologs (the positions of these hydro-
phobic amino acids are marked with stars in Fig. 1). However,
in comparing their BH3 domains, it is not apparent why N-
terminally truncated KSBcl-2 possesses proapoptotic activity
while the other viral proteins lack this activity. Perhaps a cleav-
age-dependent conformational change that exposes the bind-
ing face of the BH3 domain of Bcl-2 and Bcl-xL does not occur
in the herpesvirus homologs.
The role of heterodimerization between proapoptotic and
antiapoptotic Bcl-2 family members in blocking cell death is
not fully understood. Although Bcl-2 and Bcl-xL can prevent
cell death by mechanisms other than sequestering Bax and
Bak, heterodimerization may serve to titrate the intracellular
concentrations of these partners (9, 37). However, no consis-
tent picture has emerged with regard to heterodimerization of
viral Bcl-2 proteins. HVS Bcl-2 appears to be capable of bind-
ing and perhaps suppressing the activity of Bax (10, 50, 56),
while other viral homologs fail to heterodimerize with Bax
(e.g., KSBcl-2 and BHRF1) and potentially escape inactivation
by Bax. KSBcl-2 was recently demonstrated to bind a new
member of the Bcl-2 family, Diva/Boo, though there is contro-
versy about whether Diva/Boo is an antiapoptotic or proapo-
ptotic protein (31, 55). Like Bcl-2, Bcl-xL, and perhaps Diva/
Boo, Bax can also flip its function and become an antiapoptotic
factor (41). Thus, while both pro- and antiapoptotic cellular
Bcl-2 family proteins can reverse their functions, viral Bcl-2
homologs appear to be locked into the antiapoptotic mode.
The inability of herpesvirus Bcl-2 proteins to be cleaved by
caspases and their lack of proapoptotic activity strongly indi-
cate that these viral factors have eliminated key features of the
cellular homologs from which they were likely derived. If low
FIG. 6. Antiapoptotic activity of KSBcl-2 is resistant to inactivation by
caspase-3. Cell viability of Cos-1 cells transfected with the indicated plasmids was
determined as described in the legend to Fig. 5. The data are the means and
SEM. The effect of cotransfected procaspase-3 was statistically significant only
for wild-type Bcl-2 using a Wilcoxon signed-rank test for paired analysis of seven
independent experiments (indicated at the top). Representative immunoblots of
transfected cell lysates with the indicated antibodies are shown below. Pro,
unprocessed form of procaspase-3; Act, active cleavage product of caspase-3.
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levels of caspases become activated in healthy cells, the gen-
eration of proapoptotic fragments from target substrates such
as Bcl-2 family proteins may be necessary to amplify the apo-
ptotic pathway and facilitate cell death. Indeed, the cleavage
fragment of Bcl-2 and Bid can induce the release of cyto-
chrome c from mitochondria (35, 43). Cytochrome c serves as
an essential cofactor for Apaf-1 to activate procaspase-9, which
in turn amplifies the caspase cascade (68). Overexpression of
viral Bcl-2 proteins that fail to facilitate cell death could po-
tentially serve to tip the balance in favor of cell survival.
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